Haemonetics
197 hedge funds and large institutions have $2.11B invested in Haemonetics in 2016 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 64 increasing their positions, 79 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
13% more capital invested
Capital invested by funds: $1.87B → $2.11B (+$240M)
9% more funds holding
Funds holding: 180 → 197 (+17)
0.52% more ownership
Funds ownership: 101.01% → 101.53% (+0.52%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
19% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 79
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $486K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$43.4M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$19.6M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$16M |
| 4 |
Millennium Management
New York
|
+$13.3M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$9.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.8M |
| 3 |
VBA
Van Berkom & Associates
Montreal,
Quebec, Canada
|
-$10.1M |
| 4 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
-$9.73M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$8.12M |
HAE Hedge Fund Activity: Q4 2016 in Review
197 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2016, worth a combined $2.11B — up 13% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new HAE positions and 13 closed out — a net gain of 20 holders — while 64 added to existing stakes and 79 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $43.4M. The largest seller was Fidelity Investments, cutting an estimated $34.9M.
- 197 institutional investors held Haemonetics (HAE) as of Q4 2016, up from 180 in Q3 2016.
- Funds reported $2.11B of Haemonetics stock for Q4 2016, up 13% quarter-over-quarter.
- 33 funds opened new Haemonetics positions in Q4 2016 and 13 closed out, a net change of +20 holders.
- The largest Haemonetics buyer in Q4 2016 was HealthCor Management, an estimated $43.4M added.
- The largest Haemonetics seller in Q4 2016 was Fidelity Investments, an estimated $34.9M sold.
Based on aggregated 13F filings for Q4 2016.